Systemic and immunotoxicity of silver nanoparticles in an intravenous 28 days repeated dose toxicity study in rats

Biomaterials

Volumn 34, Issue 33, 2013, Pages 8333-8343

  De Jong, Wim H ^a   Van Der Ven, Leo T M ^a   Sleijffers, Annemarie ^a   Park, Margriet V D Z ^a   Jansen, Eugene H J M ^a   Van Loveren, Henk ^a   Vandebriel, Rob J ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

28 Days repeated dose study; Intravenous; Nanosilver; Nanotoxicity

Indexed keywords

28 DAYS REPEATED DOSE STUDY; ALKALINE PHOSPHATASE; ANTI-BACTERIAL ACTIVITY; INTRAVENOUS; INTRAVENOUS ADMINISTRATION; NANO SILVER; NANOTOXICITY; SILVER NANOPARTICLES;

AMINO ACIDS; ANIMALS; ANTHROPOMETRY; BIOCHEMISTRY; BODY FLUIDS; CELL CULTURE; CELL PROLIFERATION; CELLS; CONSUMER PRODUCTS; INDUSTRIAL POISONS; NANOPARTICLES; PHOSPHATASES; RATS; TOXICITY;

SILVER;

CONCANAVALIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN M; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MITOGENIC AGENT; SILVER NANOPARTICLE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CELL COUNT; CLINICAL CHEMISTRY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG TOLERABILITY; FEMALE; GROWTH RETARDATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IMMUNOTOXICITY; LIVER; LIVER INJURY; LYMPH NODE; LYMPHOCYTE SUBPOPULATION; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; ORGAN WEIGHT; PARTICLE SIZE; POPULATION; PRIORITY JOURNAL; RAT; SPLEEN; SPLEEN CELL; SPLEEN SIZE; T LYMPHOCYTE; THYMUS; WEIGHT;

ANIMALIA; RATTUS;

28 DAYS REPEATED DOSE STUDY; INTRAVENOUS; NANOSILVER; NANOTOXICITY;

ADMINISTRATION, INTRAVENOUS; ANIMALS; FEMALE; IMMUNE SYSTEM; KILLER CELLS, NATURAL; MALE; METAL NANOPARTICLES; RATS; RATS, WISTAR; SILVER; SPLEEN;

EID: 84881663479     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.06.048     Document Type: Article

References (28)

1. Roszek B., De Jong W.H., Geertsma R.E. Nanotechnology in medical applications: state-of-the-art in materials and devices 2005, RIVM report 265001001, RIVM, Bilthoven, The Netherlands, Available from:. http://www.rivm.nl/bibliotheek/rapporten/265001001.html.
2. Chen X., Schleusener H.J. Nanosilver: a nanoproduct in medical application. Toxicol Lett 2008, 176:1-12.
3. Rai M., Yadav A., Gade A. Silver nanoparticles as a new generation of antimicrobials. Biotechnol Adv 2009, 27:76-83.
4. Wijnhoven S.W.P., Peijnenbeurg W.J.G.M., Herberts C.A., Hagens W.I., Oomen A.G., Heugens E.H.W., et al. Nano-silver - a review of available data and knowledge gaps in human and environmental risk assessment. Nanotoxicology 2009, 3:109-138.
5. Wijnhoven S.W.P., Dekkers S., Hagens W.I., De Jong W.H. Exposure to nanomaterials in consumer products 2009, RIVM report 340370001, RIVM, Bilthoven, The Netherlands, Available from:. http://www.rivm.nl/bibliotheek/rapporten/340370001.html.
6. Woodrow Wilson International Centre for Scholars Project on emerging nanotechnologies. Consumer products inventory of nanotechnology products March 10, 2011, Washington, USA. Available from:. http://www.nanotechproject.org/inventories/consumer/analysis_draft/.
7. Lem K.W., Choudhury A., Lakhani A.A., Kuyate P., Haw J.R., Lee D.S., et al. Use of nanosilver in consumer products. Recent Patents on Nanotechnol 2012, 6:60-72.
8. Dekkers S., Prud'homme De Lodder L.C.H., De Winter R., Sips A.J.A.M., De Jong W.H. Inventory of consumer products containing nanomaterials 2007, RIVM report 340120001. Available from:. http://www.rivm.nl/bibliotheek/rapporten/340120001.
9. Christensen F.M., Johnston H.J., Stone V., Aitken R.J., Hankin S., Peters S., et al. Nano-silver e feasibility and challenges for human health risk assessment based on open literature. Nanotoxicology 2010, 4:284-295.
10. Stensberg M.C., Wei Q., McLamore E.S., Porterfield D.M., Wei A., Sepulveda M.S. Toxicological studies on silver nanoparticles: challenges and opportunities in assessment, monitoring and imaging. Nanomedicine 2011, 6:879-898.
11. Pronk M.E.J., Wijnhoven S.W.P., Bleeker E.A.J., Heugens E.H.W., Peijnenburg W.J.G.M., Luttik R., et al. Nanomaterials under REACH. Nanosilver as a case study 2009, RIVM, Bilthoven, The Netherlands, RIVM report 601780003. Available from:. http://www.rivm.nl/bibliotheek/rapporten/601780003.html.
12. De Jong W.H., Hagens W.I., Krystek P., Burger M.C., Sips A.J.A.M., Geertsma R.E. Particle size dependent organ distribution of gold nanoparticles after intervenous administration. Biomaterials 2008, 29:1912-1919.
13. Lankveld D.P., Oomen A.G., Krystek P., Neigh A., Troost-de Jong A., Noorlander C.W., et al. The kinetics of the tissue distribution of silver nanoparticles of different sizes. Biomaterials 2010, 31:8350-8361.
14. Lankveld D.P.K., Rayavarapu R.G., Krystek P., Oomen A.G., Verharen H.W., Van Leeuwen T.G., et al. Blood clearance and tissue distribution of PEGylated and non-PEGylated gold nanorods after intravenous administration in rats. Nanomedicine 2011, 6:339-349.
15. Park M.V.D.Z., Neigh A.M., Vermeulen J.P., De La Fonteyne L.J.J., Verharen H.W., Briedé J.J., et al. The effect of particle size on the cytotoxicity, inflammation, developmental toxicity and genotoxicity of silver nanoparticles. Biomaterials 2011, 32:9810-9817.
16. Ji J.H., Jung J.H., Kim S.S., Yoon J.U., Park J.D., Choi B.S., et al. Twenty eight day inhalation toxicity study of silver nanoparticles in Sprague-Dawley rats. Inhal Toxicol 2007, 19:857-871.
17. Sung J.H., Ji J.H., Park J.D., Yoon J.U., Kim D.S., Jeon K.S., et al. Subchronic inhalation toxicity of silver nanoparticles. Toxicol Sc 2009, 108:452-461.
18. Song K.S., Sung J.H., Ji J.H., Lee J.H., Lee J.S., Ryu1 H.R., et al. Recovery from silver-nanoparticle-exposure-induced lung inflammation and lung function changes in Sprague Dawley rats. Nanotoxicology 2013, 7:169-180.
19. Kim Y.S., Kim J.S., Cho H.S., Rha D.S., Kim J.M., Park J.D., et al. Twenty-eight day oral toxicity, genotoxicity, and gender related tissue distribution of silver nanoparticles in Sprague-Dawley rats. Inhal Toxicol 2008, 20:575-583.
20. Van Der Zande M., Vandebriel R.J., Van Doren E., Kramer E., Herrera Rivera Z., Serrano-Rojero C.S., et al. Distribution, elimination, and toxicity of silver nanoparticles and silver ions in rats after 28-day oral exposure. ACSnano 2012, 6:7427-7442.
21. EFSA Scientific Opinion Use of the bench mark dose approach in risk assessment. EFSA J 2009, 1150:1-72.
22. Tonk E.C., de Groot D.M., Penninks A.H., Waalkens-Berendsen I.D., Wolterbeek A.P., Slob W., et al. Developmental immunotoxicity of methylmercury: the relative sensitivity of developmental and immune parameters. Toxicol Sci 2010, 117:325-335.
23. De Jong W.H., Kroese E.D., Vos J.G., Van Loveren H. Detection of immunotoxicity of benzo[a]pyrene in a subacute toxicity study after oral exposure in rats. Tox Sc 1999, 50:214-220.
24. Slob W., Pieters M.N. Aprobabilistic approach for deriving acceptable human intake limits and human health risks from toxicological studies: general framework. Risk Anal 1998, 18:787-798.
25. Slob W. Dose-response modeling of continuous endpoints. Toxicol Sc 2002, 66:298-312.
26. Park E.J., Bae E., Yi J., Kim Y., Choi K., Lee S.H., et al. Repeated dose toxicity and inflammatory responses in mice by oral administration of silver nanoparticles. Environm Toxicol Pharmacol 2010, 30:162-168.
27. De Jong W.H., Van Loveren H. Screening of xenobiotics for direct immunotoxicity in an animal study. Methods 2007, 41:3-8.
28. Beer C., Foldbjerg R., Hayashi Y., Sutherland D.S., Autrup H. Toxicity of silver nanoparticles - nanoparticle or silver ion?. Toxicol Lett 2012, 208:286-292.